|
Jul 25
|
Idorsia announces financial results for the first half 2024
|
|
Jun 25
|
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
|
|
Jun 21
|
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
|
|
May 14
|
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
|
|
May 10
|
Q1 2024 Viatris Inc Earnings Call
|
|
May 6
|
Bondholders approve amended terms of the 2024 convertible bonds
|
|
Mar 22
|
Idorsia thanks Guy Braunstein for his years of service as he retires
|
|
Mar 20
|
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
|
|
Jan 10
|
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
|
|
Dec 6
|
Idorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insiders
|